Check out our FREE Resources page – Download complimentary business frameworks, PowerPoint templates, whitepapers, and more.

Pharma Disease Insight: Breast Cancer (Oncology)   31-slide PPT PowerPoint presentation (PPTX)

Pharma Disease Insight: Breast Cancer (Oncology) (31-slide PPT PowerPoint presentation (PPTX)) Preview Image Pharma Disease Insight: Breast Cancer (Oncology) (31-slide PPT PowerPoint presentation (PPTX)) Preview Image Pharma Disease Insight: Breast Cancer (Oncology) (31-slide PPT PowerPoint presentation (PPTX)) Preview Image Pharma Disease Insight: Breast Cancer (Oncology) (31-slide PPT PowerPoint presentation (PPTX)) Preview Image Pharma Disease Insight: Breast Cancer (Oncology) (31-slide PPT PowerPoint presentation (PPTX)) Preview Image Pharma Disease Insight: Breast Cancer (Oncology) (31-slide PPT PowerPoint presentation (PPTX)) Preview Image Log in to unlock full preview.
Arrow   Unlock all 12 preview images:   Login Register

Pharma Disease Insight: Breast Cancer (Oncology) (PowerPoint PPTX)

File Type: 31-slide PPT PowerPoint presentation (PPTX)

#2 in Oncology $99.00

Add to Cart


Immediate digital download upon purchase.
Lifetime document updates included with purchase.
Fully editable & customizable PPTX document.
Trusted by over 10,000+ organizations.


This product (Pharma Disease Insight: Breast Cancer [Oncology]) is a 31-slide PPT PowerPoint presentation (PPTX), which you can download immediately upon purchase.

The breast cancer therapy market was the largest in oncology across the major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) in 2015 with sales of $13.8 billion. Sales are set to soar throughout our forecast period to $30.5 billion by 2025, driven by uptake of both current and emerging agents in multiple treatment settings. Two drug classes, HER2-targeted agents and CDK4/6 inhibitors, will account for over 60% of sales in this market in 2025.

Currently approved therapies will continue to have a meaningful impact on the breast cancer treatment algorithm and market sales. Pfizer's CDK4/6 inhibitor Ibrance will experience increasing use in the HR-positive, HER2-negative population, fueling this agent's sales to exceed $8.5 billion at its peak. Roche/Genentech/Chugai's HER2-targeted MAb, Perjeta, will continue to gain traction in the market, with its forecast adjuvant approval bolstering sales to exceed $5 billion in 2025.

1. Key Findings
2. Market Share of Colorectal Cancer Drug Classes in 2015 and 2025
3. Disease Market SWOT Analysis
1. Key Findings
2. Expert Insight
3. Disease Overview
4. Disease Pathophysiology
5. Etiology
6. Pathophysiology
1. Key Findings
2. Expert Insight
3. Market Overview
4. What Factors Are Driving the Market
5. What Factors Are Constraining the Market

Got a question about the product? Email us at or ask the author directly by using the "Ask the Author a Question" form. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Best Practices in Cancer PowerPoint Slides: Pharma Disease Insight: Breast Cancer (Oncology) PowerPoint (PPTX) Presentation, BigPharma2000


Add to Cart


File Type: PowerPoint pptx (PPTX)
File Size: 2 MB
Number of Slides: 31 (includes cover and all slides)


Author: BigPharma2000
Additional documents from author: 40

Ask the Author a Question

Must be logged in

Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.
Bundle and save! You can save up to % with bundles!

View bundle(s)

Trusted by over 10,000+ Client Organizations
Since 2012, we have provided best practices to over 10,000 businesses and organizations of all sizes, from startups and small businesses to the Fortune 100, in over 130 countries.
AT&T GE Cisco Intel IBM Coke Dell Toyota HP Nike Samsung Microsoft Astrazeneca JP Morgan KPMG Walgreens Walmart 3M Kaiser Oracle SAP Google E&Y Volvo Bosch Merck Fedex Shell Amgen Eli Lilly Roche AIG Abbott Amazon PwC T-Mobile Broadcom Bayer Pearson Titleist ConEd Pfizer NTT Data Schwab

Read Customer Testimonials

Save with Bundles

This document is available as part of the following discounted bundle(s):

Save %!
Pharma Disease Insights: Oncology

This bundle contains 5 total documents. See all the documents to the right.


Add Bundle & Save

Customers Also Bought These Documents

Customers Also Like These Documents

Related Management Topics

Healthcare Cancer Consulting Frameworks Strategic Planning Strategy Frameworks Strategic Thinking Gap Analysis Consulting Training Financial Analysis Management Accounting Market Research Organizational Design Presentation Development Pyramid Principle Meeting Facilitation/Management Financial Management Strategic Analysis Disruption Budgeting & Forecasting Scenario Planning Chief Strategy Officer Strategy Development Positioning

Download our FREE Strategy & Transformation Framework Templates

Download our free compilation of 50+ Strategy & Transformation slides and templates. Frameworks include McKinsey 7-S Strategy Model, Balanced Scorecard, Disruptive Innovation, BCG Experience Curve, and many more.